AdaptHealth director buys 8,000 AHCO shares

AdaptHealth Corp. director Dale B. Wolf reported an open-market purchase of common stock.

Rhea-AI Filing Summary

AdaptHealth Corp. director Dale B. Wolf reported an open-market purchase of common stock. On February 27, 2026, he bought 8,000 shares of AdaptHealth common stock at a weighted average price of $8.96 per share.

After this transaction, Wolf directly owned 104,235 common shares. The filing also reports an additional 14,000 common shares held indirectly by a trust, reflecting indirect ownership separate from his direct holdings.

Insider Trade Summary

Net Buyer: 8,000 shares

Net Buy 2 txns

Insider WOLF DALE B

Role Director

Bought 8,000 shs ($72K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	8,000	$8.96	$72K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 104,235 shares (Direct); Common Stock — 14,000 shares (Indirect, By Trust)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.94 to $8.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) .

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AdaptHealth (AHCO) report for Dale B. Wolf?

AdaptHealth (AHCO) reported that director Dale B. Wolf bought 8,000 shares of common stock. The open-market purchase occurred on February 27, 2026, and reflects increased direct ownership, as disclosed in a Form 4 insider trading filing with the Securities and Exchange Commission.

How many AdaptHealth (AHCO) shares does Dale B. Wolf own after the Form 4 transaction?

After the reported transaction, Dale B. Wolf directly owns 104,235 shares of AdaptHealth common stock. The filing also shows 14,000 additional shares held indirectly through a trust, indicating both direct and indirect beneficial ownership positions in AHCO’s common stock.

What was the purchase price per share in the AdaptHealth (AHCO) Form 4 filing?

The Form 4 shows a weighted average purchase price of $8.96 per AdaptHealth share. The 8,000 shares were bought in multiple open-market trades on February 27, 2026, all within a narrow price range around this reported average value.

Was the AdaptHealth (AHCO) Form 4 transaction a buy or a sell?

The Form 4 for AdaptHealth (AHCO) reports a buy transaction by director Dale B. Wolf. He executed an open-market purchase of 8,000 common shares, increasing his direct holdings as reflected in the post-transaction ownership figures in the filing.

How many AdaptHealth (AHCO) shares were traded in total in Dale B. Wolf’s Form 4?

The filing shows that 8,000 AdaptHealth common shares were purchased in the reported transaction. This net buy increased Wolf’s direct ownership to 104,235 shares, while indirect holdings through a trust remain reported at 14,000 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WOLF DALE B

(Last) (First) (Middle)

C/O ADAPTHEALTH LLC

555 EAST NORTH LANE, SUITE 5075

(Street)

CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		P		8,000	A	$8.96(1)	104,235	D
Common Stock								14,000	I	By Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.94 to $8.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) .

	/s/ Richard Rew, as attorney-in-fact for Dale Wolf	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.